SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Hepatocellular Carcinoma Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with hepatocellular carcinoma (HCC). Recently, the checkpoint inhibitor atezolizumab was approved by the U.S. FDA in combination with the anti-VEGF therapy bevacizumab as a first-line treatment for HCC. Additional immunotherapies targeting the PD-(L)-1 axis are approved second-line options. Ongoing trials are evaluating additional immunotherapeutic strategies for this disease state. Reflecting the evolving therapeutic landscape, SITC is currently developing an HCC CPG with topics including selection of appropriate immunotherapeutic regimens, recognition and management of adverse events, and patient quality of life considerations.
Published September 12, 2021 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma"
SITC is pleased to offer companion educational resources in support of the published Hepatocellular Carcinoma CPG. These activities feature faculty comprised of the guideline expert panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios. The educational available features both webinars which are a longer-format recording that takes a deeper look at the guideline recommendations as well as mini-modules which are brief videos on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG available free and on-demand.
*This webinar has no external funding sources.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org